Innate Pharma Closes Partnership with Sobi Amid Financial Update
Innate Pharma (NASDAQ:IPHA) has closed a partnership deal with Sobi, triggering an upfront payment of $75 million. The company reported a €19.6 million net loss for the first half of 2026 but expects this funding—alongside a recent equity raise totaling €30 million—to extend its financial runway through early 2028. The partnership allows Sobi to take exclusive global commercialization rights upon potential accelerated approval, with Innate retaining milestone and royalty payments. The company is preparing for the Phase 3 TELLOMAK-3 trial of lacutamab in Q1 2027 but faces challenges ensuring funding covers this critical phase through completion. In addition to the partnership, operating expenses have decreased due to workforce adjustments and study timing, offering a more stable financial foundation. However, future spending will depend heavily on clinical progress.
